Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients

Huang, He; Cai, Minglong; Hong, Xiaojie; Zheng, Lijun; Hu, Zhulin; Yuan, Tao; Li, Wei-ran; Sheng, Yujun; Zhang, Xuejun

doi:10.1684/ejd.2020.3878

Cited by 17 publications

(21 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A high BMI is a well‐known negative predictor of psoriasis response to some biologic treatment as anti‐TNFalpha, ustekinumab and secukinumab 16–18 . High weight does not seem to compromise the response to brodalumab, 19 the role of the weight in the response to ixekizumab shows contradictory results in the current literature 18,20 .…”

Section: Discussionmentioning

confidence: 99%

Risankizumab shows high efficacy and maintenance in improvement of response until week 52

Mastorino

Susca

Megna

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Risankizumab has been recently approved for moderate‐to‐severe plaque psoriasis; however, real‐life studies are scarce. Analysis of possible predictor factors of treatment response are limited to body mass index (BMI) and previous biologic experience. Our objectives were to evaluate the effectiveness and safety of Risankizumab and to investigate on possible predictor factors response. We retrospectively analyzed 166 patients from two centers in Italy who undergone Risankizumab for psoriasis. The proportion of patients achieving a 100%, 90%, 75% of improvement in Psoriasis Area Severity Index (PASI) and PASI <3 were collected at weeks 16, 28, 40, and 52. Study population was analyzed in subgroups to investigate possible predictors of response to Risankizumab since week 40. At the time of analysis 165, 103, 30, and 11 patients had completed 16, 28, 40, and 52 weeks of treatment, respectively. The mean PASI score decreased from 12.5 ± 5.1 at baseline to 1.9 ± 2.4 at week 16. Similar reductions were observed when considering PASI <3, PASI 75, PASI 90, and PASI 100. Previous biologics failure, different smoking habits, obesity, and joint involvement resulted in a lower response to risankizumab. In particular, significant differences in mean PASI at any time‐points was observed between psoriatic arthritis (PSA) and non‐PSA patients: 2.7 versus 1.7 (p = 0.036), 1.9 versus 0.4 (p = 0.006), and 4.1 versus 0.5 (p = 0.016) at 16, 28, and 40 weeks, respectively. No difference in response to risankizumab occurred in the case of involvement of difficult‐to‐treat areas. In this population, Risankizumab was effective and safe. Smoking habits, joint involvement, obese status, and previous biologic experience may negatively affect treatment response, while difficult body sites involvement have minor impact.

show abstract

Section: Discussionmentioning

confidence: 99%

Risankizumab shows high efficacy and maintenance in improvement of response until week 52

Mastorino

Susca

Megna

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Although there have been some real-world studies on the efficacy and safety of secukinumab, study in China is limited. Recently, Huang et al [ 4 ] reported secukinumab 300 mg was effective for the majority of Chinese plaque psoriasis patients after 16 weeks of treatment. The PASI 75, PASI 90, and PASI 100 were 91.1%, 73.0%, and 38.3%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study

Zhao

Cai

Liu

et al. 2021

Chinese Medical Journal

View full text Add to dashboard Cite

Background: There have been few real-life dose-comparing studies on the efficacy and safety of secukinumab in Chinese patients with plaque psoriasis. We conducted a real-life cohort study to investigate the efficacy and safety of secukinumab 150 and 300 mg in Chinese patients with moderate-to-severe plaque psoriasis. Methods: A total of 106 patients with moderate-to-severe plaque psoriasis were included in this study. Patients received either secukinumab 150 mg or secukinumab 300 mg according to patients’ weights and severity of psoriasis. The treatment continued for at least 24 weeks. The efficacy was evaluated by improvement in the psoriasis area and severity index (PASI) scores. The safety was also analyzed. Results: Fifty-nine patients (55.7%) were treated with secukinumab 300 mg and 47 patients (44.3%) were treated with secukinumab 150 mg. After 12-week treatment, PASI75/90/100 responses were achieved in 100%, 97.8%, and 95.7% of patients, respectively, in secukinumab 150 mg group, and the efficacy was maintained to week 24. In secukinumab 300 mg group, PASI75/90/100 responses were achieved in 93.2%, 81.4%, and 76.3% of patients, respectively, at week 12. In this group, PASI75/90/100 responses reached 91.5%, 86.4%, and 79.9%, respectively, at week 24. Biologic-experienced patients had lower responses than biologic-naïve patients. Secukinumab 150 and 300 mg were well tolerated. Five patients discontinued treatment due to poor response, adverse event, or economic reasons. Conclusions: This real-life study demonstrated that high PASI 90 and PASI 100 responses were achieved in Chinese psoriasis patients receiving secukinumab 150 or 300 mg. Biologic-naïve was associated with better clinical efficacy.

show abstract

“…Only few real-life studies with short-term follow-up cases have been conducted to investigate the outcomes of secukinumab in China. [3][4][5] This study aimed to examine the efficacy, safety, and drug survival of secukinumab in patients with moderate-to-severe plaque psoriasis who were treated with secukinumab between May 2019 and March 2020 and followed up for over 52 weeks in China.…”

Section: Introductionmentioning

confidence: 99%

“…Nonetheless, thus far, post‐marketing data on the mid‐term and long‐term real‐life performance of secukinumab are limited, especially over the long term. Only few real‐life studies with short‐term follow‐up cases have been conducted to investigate the outcomes of secukinumab in China 3–5 …”

Section: Introductionmentioning

confidence: 99%

A retrospective study to assess the efficacy, safety, and drug survival of secukinumab in plaque psoriasis patients in China

Wang

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

Secukinumab, a full human immunoglobulin G1κ monoclonal antibody that targets interleukin‐17A, has demonstrated remarkable efficacy and appreciable tolerance in patients with moderate‐to‐severe psoriasis. However, data on its real‐life performance, particularly on drug survival in China are limited. To investigate the efficacy, safety, and drug survival of secukinumab in Chinese patients with psoriasis, we conducted a monocentric retrospective study of 66 patients with moderate‐to‐severe psoriasis to followed‐up for 52 weeks. At week 12, 86.4%, 57.6%, and 10.6% of the patients attained 75% improvement in psoriasis area and severity Index (PASI) score from baseline (PASI 75), PASI 90, and PASI 100 responses, respectively. The quality of life of patients markedly improved. The overall survival rate was 74.2%. Adverse events occurred in 30 patients (45.5%). The results revealed favorable efficacy, safety, and tolerability of secukinumab in the treatment of patients with psoriasis and provided data on drug survival in real‐life clinical setting in China for the first time.

show abstract

Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients

Cited by 17 publications

References 15 publications

Risankizumab shows high efficacy and maintenance in improvement of response until week 52

Risankizumab shows high efficacy and maintenance in improvement of response until week 52

Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study

A retrospective study to assess the efficacy, safety, and drug survival of secukinumab in plaque psoriasis patients in China

Contact Info

Product

Resources

About